Lista de obras - Rosanna Santoro - Dominio Público Uruguay

A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.

artículo científico publicado en 2001

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

artículo científico publicado en 2010

Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors.

artículo científico publicado en 2005

Erratum: Corrigendum: Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes

artículo científico publicado en 2015

High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.

artículo científico publicado en 2002

IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients

artículo científico publicado en 2011

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR ⬇️

artículo científico publicado el 10 de enero de 2011

Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients

artículo científico

Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study

article

Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring

artículo científico publicado en 2011

Linkage analysis identifies gene carriers among members of families with hereditary nonpolyposis colorectal cancer

artículo científico publicado en 1996

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

artículo científico publicado en 2005

Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes

artículo científico publicado en 2014

Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.

artículo científico publicado en 2016

The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin